Preclinical Development
The faculty and staff of the Sealy Center for Vaccine Development
strive to create, perfect and promote the most effective and
safest disease prevention strategies.
To take a vaccine from the discovery phase to the marketplace requires a few steps in between. Before vaccines can be tested in human clinical trials, researchers must do preclinical testing for safety and efficacy. At UTMB, the Sealy Center for Vaccine Development has experience with basic research and preclinical development, and internationally-recognized expertise in emerging and neglected infectious diseases. The Center also has excellent resources and access to the university’s many core facilities. The SCVD can assist scientists with:
- In vitro and in vivo research and development of biologically relevant animal models to study multiple diseases
- Development and evaluation of new adjuvants and novel vaccine platforms
- Immunogenicity testing and in vitro antiviral screening using high-throughput robotic equipment
- Safety and toxicology studies in a variety of test systems
- Preclinical development research in accordance with a quality system based on the principles of Good Laboratory Practices (GLP).
UTMB has the research infrastructure available in state-of-the-art ACL2/3, BSL2/ABSL2, BSL3/ABSL3, and BSL4/ABSL4 capacity and aerosol challenge facilities. The SCVD welcomes collaborations with individual investigators, companies and government agencies, both locally and internationally.
